Specialized Cancer Center Support Grant
专门癌症中心支持补助金
基本信息
- 批准号:8895268
- 负责人:
- 金额:$ 379.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-07-01 至 2019-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The UC San Diego (UCSD) Moores Cancer Center (MCC) has a rich history as a matrix, NCI-designated comprehensive cancer center, now with 239 members from 28 UCSD departments. Peer-reviewed MCC funding is $118.3 million (direct costs), of which $33.2 million is from the NCI. An additional $15.6 million from non-peer-reviewed sources results in total direct-cost funding of $133.9 million. We have published over 4000 cancer-focused papers in the funding period (20% inter- or intra-programmatic; 10% in journals with an impact factor >15). MCC is surrounded by several other major life-science research institutes and 489 biotechnology companies in San Diego/La Jolla, the 2"'' largest life-sciences cluster in the US. MCC is the only NCI-designated comprehensive cancer center in this region. MCC leverages this advantage to save lives by transforming cancer prevention, detection, and care (mission) and to make personalized cancer medicine a reality (vision). This is our first renewal application as a consortium center with partner San Diego State University (SDSU), thus formalizing long-standing, productive collaborations between MCC and SDSU. As designed, the MCC building 1) stimulates interdisciplinary collaboration between physicians and scientists in the Center's Divisions of Basic Science, Clinical Science, and Population Science, 2) assembles the extensive NCI-supported Shared Resources in a common, accessible site, and 3) acts as an academia-industry hub for translational cancer researchers within the public and private sectors of San Diego. The vast majority of members are in the MCC building or on the UCSD campus; others are in nearby La Jolla institutes. This application reports on six Research Programs: Cancer Biology and Signaling, Cancer Genomes and Networks, Hematologic Malignancies, Solid Tumor Therapeutics, Cancer Prevention, and Reducing Cancer Disparities. We also propose seven Shared Resources: Biorepository and Tissue Technology, Biostatistics, Genomics and Bioinformatics, Microscopy, Flow Cytometry, Transgenic Mouse, Diet and Physical Activity. All Programs and Resources reflect the scientific strengths and goals of the MCC. MCC is poised to leverage its exceptional basic and population sciences and San Diego-wide collaborations (academic and private-sector) in developing innovative science-based cancer prevention and treatment. This application summarizes our investments, recruitments, collaborations, organizational changes, plans, and progress toward this goal.
CCSG funding advances the UCSD Moores Cancer Center mission to save lives by transforming cancer prevention, detection, and care, and vision to make personalized cancer medicine a reality. The Cancer Center places the highest priority on basic discovery and its translation (via leveraging San Diego's unique academia-industry environment) into major clinical advances that reduce the burden of cancer.
描述(由申请人提供):加州大学圣地亚哥分校(UCSD)穆尔斯癌症中心(MCC)作为一个矩阵,NCI指定的综合性癌症中心有着丰富的历史,现在有来自28个UCSD部门的239名成员。经同行审查的管理协委会供资为1.183亿美元(直接费用),其中3 320万美元来自国家癌症研究所。另有1 560万美元来自未经同行审查的来源,直接费用供资总额为1.339亿美元。在资助期间,我们发表了4000多篇以癌症为重点的论文(20%是跨项目或项目内的; 10%是在影响因子>15的期刊上发表的)。MCC被其他几个主要的生命科学研究机构和489家生物技术公司包围在圣地亚哥/拉霍亚,这是美国最大的生命科学集群。MCC是该地区唯一一家NCI指定的综合性癌症中心。MCC利用这一优势,通过改变癌症预防、检测和护理(使命)来挽救生命,并使个性化癌症医疗成为现实(愿景)。这是我们作为合作伙伴圣地亚哥州立大学(SDSU)的联盟中心的第一次续约申请,从而正式确定了MCC和SDSU之间长期有效的合作。按照设计,MCC大楼1)促进中心基础科学,临床科学和人口科学部门的医生和科学家之间的跨学科合作,2)在一个共同的,可访问的网站上汇集了广泛的NCI支持的共享资源,3)作为圣地亚哥公共和私营部门内转化癌症研究人员的医学产业中心。绝大多数成员都在MCC大楼或UCSD校园内,其他人则在附近的拉霍亚学院。本申请报告了六个研究项目:癌症生物学和信号传导,癌症基因组和网络,血液肿瘤,实体瘤治疗,癌症预防和减少癌症差异。我们还提出了七个共享资源:生物储存和组织技术,生物统计学,基因组学和生物信息学,显微镜,流式细胞术,转基因小鼠,饮食和体育活动。所有计划和资源都反映了MCC的科学优势和目标。MCC准备利用其卓越的基础和人口科学以及圣地亚哥范围内的合作(学术和私营部门),开发创新的基于科学的癌症预防和治疗。此应用程序总结了我们的投资,招聘,合作,组织变革,计划和实现这一目标的进展。
CCSG的资助推进了UCSD Moores癌症中心的使命,通过改变癌症预防、检测和护理来挽救生命,并使个性化癌症医学成为现实。癌症中心将基础发现及其转化(通过利用圣地亚哥独特的制药工业环境)置于最高优先级,以减少癌症负担。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SCOTT M LIPPMAN其他文献
SCOTT M LIPPMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SCOTT M LIPPMAN', 18)}}的其他基金
Biology of the Prostate Cancer Prevention Trial (PCPT)
前列腺癌预防试验 (PCPT) 的生物学
- 批准号:
6907173 - 财政年份:2005
- 资助金额:
$ 379.56万 - 项目类别:
Biology of the Prostate Cancer Prevention Trial (PCPT)
前列腺癌预防试验 (PCPT) 的生物学
- 批准号:
7418582 - 财政年份:2005
- 资助金额:
$ 379.56万 - 项目类别:
IGF-1Axis and Insulin Resistance in PCPT
PCPT 中的 IGF-1 轴和胰岛素抵抗
- 批准号:
7102930 - 财政年份:2005
- 资助金额:
$ 379.56万 - 项目类别:
Genotypic and Phenotypic Studies of Inflammation in PCPT
PCPT 炎症的基因型和表型研究
- 批准号:
7102931 - 财政年份:2005
- 资助金额:
$ 379.56万 - 项目类别:
Biology of the Prostate Cancer Prevention Trial (PCPT)
前列腺癌预防试验 (PCPT) 的生物学
- 批准号:
7059466 - 财政年份:2005
- 资助金额:
$ 379.56万 - 项目类别:
相似国自然基金
中国北方人群肺癌患者Cancer/Testis抗原表达谱绘制表位鉴定及功能性抗原特异性CTL制备研究
- 批准号:81673007
- 批准年份:2016
- 资助金额:54.0 万元
- 项目类别:面上项目